Fine-structure deletion mapping of 10q22–24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways
Jen Jen Yeh
Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Charles A. Dana Human Cancer Genetics Unit, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts
Department of Surgery, Boston University School of Medicine, Boston, Massachusetts
Search for more papers by this authorDebbie J. Marsh
Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Charles A. Dana Human Cancer Genetics Unit, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorJan Zedenius
Center for Metabolism and Endocrinology, Department of Surgery, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
Search for more papers by this authorTrisha Dwight
Molecular Genetics Laboratory, Royal North Shore Hospital, Department of Medicine, University of Sydney, St. Leornards, NSW, Australia
Search for more papers by this authorLeigh Delbridge
Department of Surgery, Royal North Shore Hospital and University of Sydney, Sydney, Australia
Search for more papers by this authorBruce G. Robinson
Molecular Genetics Laboratory, Royal North Shore Hospital, Department of Medicine, University of Sydney, St. Leornards, NSW, Australia
Search for more papers by this authorCorresponding Author
Charis Eng
Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Cancer Research Campaign Human Cancer Genetics Research Group, University of Cambridge, Cambridge, United Kingdom
Human Cancer Genetics Program, Ohio State University Comprehensive Cancer Center, 690C Medical Research Facility, 420 W. 12th Avenue, Columbus, OH 43210.Search for more papers by this authorJen Jen Yeh
Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Charles A. Dana Human Cancer Genetics Unit, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts
Department of Surgery, Boston University School of Medicine, Boston, Massachusetts
Search for more papers by this authorDebbie J. Marsh
Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Charles A. Dana Human Cancer Genetics Unit, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorJan Zedenius
Center for Metabolism and Endocrinology, Department of Surgery, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
Search for more papers by this authorTrisha Dwight
Molecular Genetics Laboratory, Royal North Shore Hospital, Department of Medicine, University of Sydney, St. Leornards, NSW, Australia
Search for more papers by this authorLeigh Delbridge
Department of Surgery, Royal North Shore Hospital and University of Sydney, Sydney, Australia
Search for more papers by this authorBruce G. Robinson
Molecular Genetics Laboratory, Royal North Shore Hospital, Department of Medicine, University of Sydney, St. Leornards, NSW, Australia
Search for more papers by this authorCorresponding Author
Charis Eng
Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Cancer Research Campaign Human Cancer Genetics Research Group, University of Cambridge, Cambridge, United Kingdom
Human Cancer Genetics Program, Ohio State University Comprehensive Cancer Center, 690C Medical Research Facility, 420 W. 12th Avenue, Columbus, OH 43210.Search for more papers by this authorAbstract
Previous studies have demonstrated frequent loss of heterozygosity (LOH) of markers on chromosome arm 10q in both follicular thyroid carcinomas (FTCs) and follicular thyroid adenomas (FAs). A novel tumor suppressor gene, PTEN, has been mapped to 10q23.3 and is the susceptibility gene for Cowden syndrome, an autosomal dominant disorder characterized by multiple hamartomas and a risk of benign and malignant tumors of the breast and thyroid. Studies examining the relationship of somatic PTEN status and follicular thyroid neoplasms have only demonstrated a variable subset of tumors that have somatic monoallelic deletions of PTEN, suggesting that other tumor suppressor genes may be present in this region. We therefore sought to conduct a detailed examination of LOH of 20 polymorphic markers in a 19-cM region spanning 10q22–24, including PTEN, in 44 FAs and 17 FTCs. Using this fine-structure somatic mapping approach, we defined at least two novel regions of LOH in follicular adenomas and follicular carcinomas, suggesting the presence of at least two distinct tumor suppressor genes that may play a role in thyroid neoplasia. Furthermore, the difference in patterns of LOH in adenomas versus carcinomas lends additional support to the hypothesis that adenomas and carcinomas can develop along two separate, nonserial pathways. Genes Chromosomes Cancer 26:322–328, 1999. © 1999 Wiley-Liss, Inc.
REFERENCES
- Burgoyne RD, Geisow MJ. 1989. The annexin family of calcium-binding proteins. Cell Calcium 10: 1–10. Medline
- Cairns P, Tokino K, Eby Y, Sidransky D. 1994. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 54: 1422–1424. Medline
- Cairns P, Tokino K, Eby Y, Sidransky D. 1995. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 55: 224–227. Medline
- Chi H, Tiller GE, Dasouki MJ, Romano PR, Wang J, O'Keefe R J, Puzas JE, Rosier RN, Reynolds PR. 1999. Multiple inositol polyphosphate phosphatase: evolution as a distinct group within the histidine phosphatase family and chromosomal localization of the human and mouse genes to chromosomes 10q23 and 19. Genomics 56: 324–336. Medline
- Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G. 1998. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 16: 541–545. Medline
- Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C. 1997. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57: 4710–4713. Medline
- Dahia PLM, Aguiar RCT, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C, Eng C. 1999. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 8: 185–193. Medline
- Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A. 1998. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16: 2259–2264. Medline
- Eng C. 1998. Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol 12: 701–710. Medline
- Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. 1998. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743–1748. Medline
- Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboue B, Latham WC, Eng C, Mulligan LM, Longy M. 1999. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79: 718–723. Medline
- Freihoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler OD, von Deimling A, Schmutzler RK. 1999. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 79: 754–758. Medline
- Grebe SK, McIver B, Hay ID, Wu PS, Maciel LM, Drabkin HA, Goellner JR, Grant CS, Jenkins RB, Eberhardt NL. 1997. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab 82: 3684–3691. Medline
-
Halachmi N,
Halachmi S,
Evron E,
Cairns P,
Okami K,
Saji M,
Westra WH,
Zeiger MA,
Jen J,
Sidransky D.
1998.
Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors.
Genes Chromosomes Cancer
23: 239–243.
Medline
10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- Jacoby RF, Schlack S, Cole CE, Skarbek M, Harris C, Meisner LF. 1997. A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria. Gastroenterology 112: 1398–1403. Medline
- Kagan J LJ, Stein JD, Wagner SS, Babkowski R, Grossman BH, and Katz RL. 1998. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 16: 909–913. Medline
- Kim SK, Su LK, Oh Y, Kemp BL, Hong WK, Mao L. 1998. Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene 16: 89–93. Medline
- Kinzler KW, Vogelstein B. 1998. Landscaping the cancer terrain. Science 280: 1036–1037. Medline
- Kurose K, Bando K, Fukino K, Sugisaki Y, Araki T, Emi M. 1998. Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers: evidence for inactivation of both alleles. Jpn J Cancer Res 89: 842–848. Medline
- Larson AA, Kern S, Curtiss S, Gordon R, Cavenee WK, Hampton GM. 1997. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res 57: 4082–4090. Medline
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947. Medline
- Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64–67. Medline
- Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. 1997. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57: 5254–5257. Medline
- Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375–13378. Medline
- Marsh DJ, Roth S, Lunetta KL, Hemminki A, Dahia PL, Sistonen P, Zheng Z, Caron S, van Orsouw NJ, Bodmer WF, Cottrell SE, Dunlop MG, Eccles D, Hodgson SV, Jarvinen H, Kellokumpu I, Markie D, Neale K, Phillips R, Rozen P, Syngal S, Vijg J, Tomlinson IP, Aaltonen LA, Eng C. 1997a. Exclusion of PTEN and 10q22–24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res 57: 5017–5021. Medline
- Marsh DJ, Zheng Z, Zedenius J, Kremer H, Padberg GW, Larsson C, Longy M, Eng C. 1997b. Differential loss of heterozygosity in the region of the Cowden locus within 10q22–23 in follicular thyroid adenomas and carcinomas. Cancer Res 57: 500–503. Medline
- Marsh DJ, Dahia PL, Caron S, Kum JB, Frayling IM, Tomlinson IP, Hughes KS, Eeles RA, Hodgson SV, Murday VA, Houlston R, Eng C. 1998. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 35: 881–885. Medline
- Mathew CG, Smith BA, Thorpe K, Wong Z, Royle NJ, Jeffreys AJ, Ponder BA. 1987. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 328: 524–526. Medline
- Morgan RO BD, Testa JR, Fernandez MP. 1998. Genomic locations of ANX11 and ANX13 and the evolutionary genetics of human annexins. Genomics 48: 100–110. Medline
- Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. 1997. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657–3659. Medline
- Risinger JI, Hayes AK, Berchuck A, Barrett JC. 1997. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736–4738. Medline
-
Singh B,
Ittmann M,
Krolewski J.
1998.
Sporadic breast cancers exhibit loss of heterozygoisity on chomosome segment 10q23 close to the Cowden disease locus.
Genes Chromosome Cancer
21: 166–171.
Medline
10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH. 1997. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935–3940. Medline
- Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA, et al. 1997. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221–5225. Medline
-
Tung WS,
Shevlin DW,
Kaleem Z,
Tribune DJ,
Wells J,
Goodfellow PJ.
1997.
Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss.
Genes Chromosomes Cancer
19: 43–51.
Medline
10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R. 1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183–4186. Medline
- Wang SI, Parsons R, Ittmann M. 1998. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4: 811–815. Medline
- Ward LS BG, Medvedovic M, Fagin JA. 1998. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metabolism 83: 525–530. Medline
-
Wu CL,
Roz L,
McKown S,
Sloan P,
Read AP,
Holland S,
Porter S,
Scully C,
Paterson I,
Tavassoli M,
Thakker N.
1999.
DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas.
Genes Chromosomes Cancer
25: 16–25.
Medline
10.1002/(SICI)1098-2264(199905)25:1<16::AID-GCC3>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- Zedenius J, Wallin G, Svensson A, Bovee J, Hoog A, Backdahl M, Larsson C. 1996. Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. Human Gen 97 299–303. Medline
